Sanofi has announced positive Phase III results for rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor in development for immune thrombocytopenia (ITP). The French pharmaceutical company tested the treatment in adults with ITP and observed a significant improvement in platelet counts. Patients on rilzabrutinib showed a median time to first platelet response of 36 days, which is faster than placebo. Notably, responders began to see improvements as early as 15 days after treatment initiation. This promising news brings hope for patients with ITP, who often struggle with low platelet counts and anemia. Further studies will be necessary to confirm the efficacy and safety of rilzabrutinib in treating this condition.
Source: https://www.thepharmaletter.com/pharmaceutical/ash-data-set-out-benefits-of-sanofis-rilzabrutinib